17.04.2023 • News

Lummus and RWDC Link on Polyhydroxyalkanoates

Lummus Technology and US biotech RWDC Industries have signed a Memorandum of Understanding to cooperate on deploying polyhydroxyalkanoates (PHAs), a group of natural biodegradable polyesters that are a sustainable alternative to fossil-based plastics.

The collaboration combining Lummus’ expertise in process technology and RWDC’s expertise in PHA production and application is intended to significantly accelerate global availability and mass adoption of PHAs through global licensing opportunities. RWDC uses plant-based oils, including post-consumer or waste cooking oils, to produce its proprietary Solon PHA, which can be organically recycled or composted.

“We are excited to combine Lummus and RWDC’s collective expertise, experience and resources to commercialize PHAs, a sustainable and economic solution to help address global plastic waste,” said Lummus president and CEO Leon de Bruyn. “Together, we can provide eco-friendly biodegradable plastics, while driving innovation and advancing the circular economy of our industry.”

Leon de Bruyn, CEO Lummus (left)  and Daniel Carraway (right), CEO and founder,...
Leon de Bruyn, CEO Lummus (left) and Daniel Carraway (right), CEO and founder, RWDC Industries © Lummus Technology

In June 2021, RWDC announced a collaboration with US multinational personal care giant Kimberly-Clark, which aims to cut the use of fossil-based plastics by half by 2030.  Under the deal, the companies agreed to jointly develop personal care products featuring RWDC’s Solon PHA over the next five years.

Author: Elaine Burridgeeee, Freelance Journalist

Company

Logo:

Lummus Technology

5825 North Sam Houston Pkwy W #600
77086 Houston, TX
US

Company contact







Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

29 April 2026 | This webinar explores how chemical industry organizations can design a digital‑ and AI‑ready operating model focused on clarity, usability, and measurable value.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.